Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented diagnosis of B-cell CLL that has relapsed after or is refractory to at least one prior regimen. The prior regimen(s) must have included an alkylating agent and fludarabine (used in combination or separately)
ECOG \< or = 2
Willing to agree to follow the pregnancy precautions.
You may not be if
Pregnant or nursing women
Systemic treatment for B-cell CLL within 28 days of study start
Central nervous system involvement
History of renal failure requiring dialysis
Prior treatment with lenalidomide
Alemtuzumab therapy within 56 days of initiating lenalidomide treatment
